LUIS ANTONIO
ÁLVAREZ-SALA WALTHER
Catedrático de universidad
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (4)
2017
-
Cardiovascular efficacy and safety of bococizumab in high-risk patients
New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539
-
Cost-effectiveness and cost-utility analysis of apixaban versus dabigatran and rivaroxaban in the treatment and secondary prevention of venous thromboembolism
Pharmacoeconomics - Spanish Research Articles, Vol. 14, Núm. 1, pp. 7-18
2016
-
Cost-effectiveness analysis of apixaban compared to low-molecular-weight heparins and Vitamin K antagonists for treatment and secondary prevention of venous thromboembolism
Farmacia Hospitalaria, Vol. 40, Núm. 3, pp. 187-208
2003
-
A six-month, multicenter, open-label, noncomparative, prospective, observational study of the efficacy and tolerability of atorvastatin in the primary care setting (Estudio del Control de las Hiperlipidemias en Atención Primaria): The CHEAP study
Current Therapeutic Research - Clinical and Experimental, Vol. 64, Núm. 6, pp. 338-354